Heart Failure (HF) is defined by the European Society of Cardiology as a clinical syndrome characterised by symptoms such as breathlessness, ankle swelling and fatigue that may be accompanied by signs such as elevated jugular venous pressure, pulmonary crackles and peripheral oedema. HF is caused by a structural and/or functional cardiac abnormality, and results in a reduced cardiac output and...Show more
Atherosclerotic cardiovascular disease (ASCVD), a type of cardiovascular disease, that is caused by dyslipidaemia and the accumulation of lipoproteins within the arterial wall, leading to the formation of atherosclerotic plaques. These plaques grow due to continued accumulation of lipoproteins and the proliferation of smooth muscle and fibrous tissue. All these...Show more
Reporting of side effects
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance, website www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing drugsafety.dublin@novartis.com or by calling (01) 2080 612.